Mesothelioma Tumor Volumes and Survival Predictions

>

Another interesting study titled "Use" Replication-restricted "herpes virus to treat experimental human malignant mesothelioma", John C. Kucharczuk 1, Bruce Randazzo1, Michael Y. Chang, Kunjlata M. Amin, Ashraf. Elshami, Daniel H. Sterman, Nabil P. Rizk, Katherine L. Molnar-Kimber, S. Moira Brown, Alasdair R. MacLean, Leslie A. Litzky, Nigel W. Fraser, Steven M. Albelda, and Larry R. Kaiser - cancer Res first 57 February 1997; 466 - Here's an excerpt: "Abstract - changed, nonneurovirulent herpes simplex virus (HSVs) have shown promise in treating brain tumors, however, HSV-1 can infect and lyse a wide range. cell types. In this report, show that HSV-1716, mutant lack both copies of the gene encoding ICP-34, 5, can effectively treat localized IP malignancy. human malignant mesothelioma cells supported the growth of HSV-1716 and are effectively lysed in vitro. ip injection of HSV-1716 in animals with established tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-CNS-localized human malignancy, with no spread or persistence after IP injection in SCID mice bearing human tumors. These results suggest that this virus can be effective and safe for use in localized human malignancies of nonneuronal origin such as malignant mesothelioma.

Another interesting study entitled "Chemotherapy of diffuse malignant mesothelioma. Phase II trial of single-agent 5-fluorouracil and adriamycin" Vernon J. Harvey MRCP, Dr. Maurice L. Slevin MRCP, Bruce AJ Ponder al., MRCP, Anthony J. Blackshaw MA, MRCPath, Peter FM Wrigley dr FRCP - Cancer Volume 54, number 6, pages 961-964, 15 September 1984 Here's an excerpt: "Abstract - Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma is the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of an agent 5-fluorouracil. One partial response of 24 months was seen. eleven patients were were treated with a single agent Adriamycin (doxorubicin) after progression on 5-fluorouracil, and one partial response of 34 months I saw. it was concluded that 5-fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as second-line agent. "

We all owe debt of gratitude to these fine researchers for their work. If you find any of these statements of support, read the study in its entirety.